^
    Back
    Association details:
    Biomarker:EGFR C797S + EGFR T790M + EGFR exon 19 deletion
    Cancer:Non Small Cell Lung Cancer
    Drug:BBT-176 (EGFR inhibitor, Tyrosine kinase inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    Clin Cancer Res
    Title:

    BBT-176, a Novel Fourth-Generation Tyrosine Kinase Inhibitor for Osimertinib-Resistant EGFR Mutations in Non-Small Cell Lung Cancer

    Published date:
    08/15/2023
    Excerpt:
    In the clinical trial, two patients harboring EGFR 19Del/T790M/C797S in blood showed tumor shrinkage and radiologic improvements.
    DOI:
    https://doi.org/10.1158/1078-0432.CCR-22-3901
    Trial ID:
    NCT04820023